Nanobac Pharmaceuticals Announces Continuation of Space Act Agreement
with NASA: NASA to Study Characterization of the Physical and Chemical
Properties of Calcifying Nano Particles and Their Role in Calcifying
Diseases

Last Update: 9:15 AM ET Sep 18, 2007

TAMPA, Fla., Sep 18, 2007 (BUSINESS WIRE) -- Nanobac Pharmaceuticals
Inc.  ("Nanobac" or the "Company") is pleased to announce the signing
of a Space Act Agreement with NASA's Johnson Space Center (JSC),
Houston Texas, to collaborate on research on Calcifying Nanoparticles
(CNP) and its nature and role in pathological calcification, including
the detection and treatment of the pathogen. Since Astronauts may be
more prone to an increased rate of pathological calcification while in
a zero gravity environment, the collaboration will bring a new
approach to NASA's need to better understand the effects of long-term
space travel on humans.

NANOBAC and NASA are interested in pathological calcium phosphate
particles found in diseases such as kidney stones, prostatitis, and
arthritis, which are all conditions that accelerate in humans in a
zero gravity environment. This collaboration would provide NASA the
opportunity to utilize NANOBAC's diagnostic and treatment experience
in this field in support of NASA's exploration goals related to
understanding the effects of long-term space travel on humans and
offer Nanobac the opportunity to further develop its methods and
utilize NASA instrumentation to further characterize the CNPs.

Part of the instrumentation to be used is the Focused Ion Beam (FIB)
in order to mill CNP samples for use in Scanning and Transmission
Electron Microscopy (SEM, TEM, STEM) analyses to characterize internal
CNP mineralogy. Additionally, Laser Microprobe, Organic Mass-
Spectrometric analyses and Nano-SIMS elemental and isotopic analyses
will be performed to characterize the organic content of the CNPs.

"We are pleased to be able to extend our Director of Science time at
NASA for these important projects," commented Dr. Benedict Maniscalco,
Nanobac's Co-Chair and Chief Medical Officer. "We appreciate the
opportunity to work with some of the country's most talented
scientists."

Nanobac's Director of Science Neva Ciftcioglu added: "The continuation
of our collaborative research with NASA will give us an opportunity to
stay with exceptionally experienced diverse scientific members helping
us to complete the biological definition of the unique agent:
calcifying nanoparticles."

For more information, visit our website at: http://www.nanobac.com .

SOURCE: Nanobac Pharmaceuticals Inc.

Nanobac Pharmaceuticals, Tampa
Brady Millican, 813-264-2241
or
Redwood Consultants
Jens Dalsgaard, 415-884-0348